MCID: HRP004
MIFTS: 63

Herpes Zoster

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Herpes Zoster

MalaCards integrated aliases for Herpes Zoster:

Name: Herpes Zoster 12 77 26 55 56 45 15 17 3
Shingles 12 77 26 55 44 15 3 64
Zoster 26 3
Herpes Zoster Disease 74
Herpes Zona 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8536
ICD9CM 36 053
MeSH 45 D006562
NCIt 51 C71079
SNOMED-CT 69 4740000
UMLS 74 C0019360

Summaries for Herpes Zoster

MedlinePlus : 44 What is shingles? Shingles is an outbreak of rash or blisters on the skin. It is caused by the varicella-zoster virus - the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body. It may not cause problems for many years. But as you get older, the virus may reappear as shingles. Is shingles contagious? Shingles is not contagious. But you can catch chickenpox from someone with shingles. If you've never had chickenpox or the chickenpox vaccine, try to stay away from anyone who has shingles. If you have shingles, try to stay away from anyone who has not had chickenpox or the chickenpox vaccine, or anyone who might have a weak immune system. Who is at risk for shingles? Anyone who has had chickenpox is at risk for getting shingles. But this risk goes up as you get older; shingles is most common in people over age 50. People with weakened immune systems are at higher risk of getting shingles. This includes those who Have immune system diseases such as HIV/AIDS Have certain cancers Take immunosuppressive drugs after an organ transplant Your immune system may be weaker when you have an infection or are stressed. This can raise your risk of shingles. It is rare, but possible, to get shingles more than once. What are the symptoms of shingles? Early signs of shingles include burning or shooting pain and tingling or itching. It is usually on one side of the body or face. The pain can be mild to severe. One to 14 days later, you will get a rash. It consists of blisters that typically scab over in 7 to 10 days. The rash is usually a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Some people may also have other symptoms: Fever Headache Chills Upset stomach What are the complications of shingles? Shingles can cause complications: Postherpetic neuralgia (PHN) is most common complication of shingles. It causes severe pain in the areas where you had the shingles rash. It usually gets better in a few weeks or months. But some people can have pain from PHN for many years, and it can interfere with daily life. Vision loss can happen if shingles affects your eye. It may be temporary or permanent. Hearing or balance problems are possible if you have shingles within or near your ear. You may also have weakness of the muscles on that side of your face. These problems can be temporary or permanent. Very rarely, shingles can also lead to pneumonia, brain inflammation (encephalitis), or death. How is shingles diagnosed? Usually your health care provider can diagnose shingles by taking your medical history and looking at your rash. In some cases, your provider may scrap off tissue from the rash or swab some fluid from the blisters and send the sample to a lab for testing. What are the treatments for shingles? There is no cure for shingles. Antiviral medicines may help to make the attack shorter and less severe. They may also help prevent PHN. The medicines are most effective if you can take them within 3 days after the rash appears. So if you think you might have shingles, contact your health care provider as soon as possible. Pain relievers may also help with the pain. A cool washcloth, calamine lotion, and oatmeal baths may help relieve some of the itching. Can shingles be prevented? There are vaccines to prevent shingles or lessen its effects. The Centers for Disease Control and Prevention recommends that healthy adults 50 years and older get the Shingrix vaccine. You need two doses of the vaccine, given 2 to 6 months apart. Another vaccine, Zostavax, may be used in certain cases.

MalaCards based summary : Herpes Zoster, also known as shingles, is related to postherpetic neuralgia and human immunodeficiency virus infectious disease, and has symptoms including fever, paresthesia and headache. An important gene associated with Herpes Zoster is DPYD (Dihydropyrimidine Dehydrogenase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Foscarnet and Acyclovir have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Disease Ontology : 12 A viral infectious disease that results in infection located in nerve fiber, has material basis in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has symptom rash which is followed by blisters, has symptom headache, has symptom fever, has symptom malaise, has symptom itching, has symptom burning pain, and has symptom paresthesia.

Genetics Home Reference : 26 Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person's life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50.

CDC : 3 Almost 1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster, in their lifetime. There are an estimated 1 million cases of shingles each year in this country. Anyone who has recovered from chickenpox may develop shingles; even children can get shingles. However, the risk of shingles increases as you get older.

NINDS : 55 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

PubMed Health : 64 About shingles: Anyone who has already had chickenpox is at risk of developing shingles later on. Both are caused by the same virus, the varicella-zoster virus. This virus stays dormant (inactive) in the body after a chickenpox infection. But it can become active again years later and cause shingles (herpes zoster): a rash with blisters that usually forms a band across the skin and is often very painful. The rash normally only affects one side of the body.People who have been vaccinated against chickenpox can still get shingles. But this is thought to be less common than developing it after having chickenpox.Shingles is particularly common in older people. Although it can be very unpleasant, it’s usually over in about two to four weeks if there are no complications.Shingles is contagious, but only for people who have never had chickenpox. In that case the infection only causes chickenpox, and not shingles.

Wikipedia : 77 Shingles, also known as zoster or herpes zoster, is a viral disease characterized by a painful skin rash... more...

Related Diseases for Herpes Zoster

Diseases related to Herpes Zoster via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 642)
# Related Disease Score Top Affiliating Genes
1 postherpetic neuralgia 33.3 HLA-A HLA-B
2 human immunodeficiency virus infectious disease 30.8 IFNG IL10 IL2
3 anterior uveitis 30.5 HLA-A HLA-B
4 uveitis 30.5 HLA-B IFNA2 IFNG IL10
5 variola major 30.4 IFNG IL2
6 pityriasis rosea 30.4 HLA-A HLA-B
7 discoid lupus erythematosus 30.4 IFNA2 IL10
8 colitis 30.3 IFNG IL10 IL2
9 rubella 30.3 HLA-A HLA-B IL10
10 ulcerative colitis 30.3 IFNG IL10 IL2
11 folliculitis 30.3 FCGR3A IFNG
12 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.2 IFNG IL10 IL2
13 chronic graft versus host disease 30.0 IFNG IL10
14 rheumatic disease 29.9 HLA-B IFNG IL10
15 panuveitis 29.9 HLA-A HLA-B IL10
16 lepromatous leprosy 29.9 IFNG IL10 IL2
17 vogt-koyanagi-harada disease 29.9 HLA-A HLA-B IL10
18 toxic shock syndrome 29.9 IFNG IL10 IL2
19 histoplasmosis 29.9 HLA-A HLA-B IFNG
20 tetanus 29.9 IFNG IL10 IL2
21 pulmonary tuberculosis 29.9 IFNG IL10 IL2
22 autoimmune disease 29.8 COL17A1 IFNG IL10 IL2
23 severe cutaneous adverse reaction 29.8 HCP5 HLA-A HLA-B
24 acquired immunodeficiency syndrome 29.8 HCP5 HLA-B IFNA2 IFNG IL10 IL2
25 mouth disease 29.8 IFNG IL10 TRPV1
26 graft-versus-host disease 29.8 HLA-A HLA-B IFNG IL10 IL2
27 common variable immunodeficiency 29.7 IFNG IL10 IL2
28 connective tissue disease 29.7 IFNG IL10 TRPV1
29 hematopoietic stem cell transplantation 29.7 HLA-A HLA-B IFNG IL10 IL2
30 fixed drug eruption 29.7 IFNG IL2
31 poliomyelitis 29.6 FCGR3A IFNG IL10
32 cytomegalovirus retinitis 29.5 HLA-A HLA-B IFNG
33 aplastic anemia 29.5 HLA-A HLA-B IFNG IL2
34 aphthous stomatitis 29.4 HLA-A HLA-B IL10 IL2
35 dermatitis, atopic 29.4 IFNG IL10 IL2
36 burning mouth syndrome 29.4 IL2 TRPV1
37 human immunodeficiency virus type 1 29.1 HLA-A HLA-B IFNG IL10 IL2 TKT
38 malaria 28.6 GYPC HLA-A HLA-B IFNG IL10 IL2
39 geniculate herpes zoster 12.9
40 herpes zoster ophthalmicus 12.8
41 myoclonus and ataxia 12.2
42 congenital varicella syndrome 12.0
43 immunodeficiency 50 11.1
44 salivary gland disease 11.0
45 cytomegalic inclusion disease 11.0
46 aids - neurological complications 11.0
47 neurological consequences of cytomegalovirus infection 11.0
48 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0
49 immunodeficiency 24 11.0
50 idiopathic cd4-positive t-lymphocytopenia 11.0

Graphical network of the top 20 diseases related to Herpes Zoster:



Diseases related to Herpes Zoster

Symptoms & Phenotypes for Herpes Zoster

Symptoms:

12
  • fever
  • paresthesia
  • headache
  • malaise
  • itching
  • rash which is followed by blisters
  • burning pain

UMLS symptoms related to Herpes Zoster:


seizures, tremor, fever, angina pectoris, pruritus, back pain, pain, headache, syncope, chronic pain, sciatica, exanthema, vertigo/dizziness, equilibration disorder, sleeplessness

Drugs & Therapeutics for Herpes Zoster

PubMedHealth treatment related to Herpes Zoster: 64

Pain and fever can be relieved with medication such as acetaminophen (paracetamol) or acetylsalicylic acid (the drug in medicines like Aspirin). Prescription painkillers are sometimes used to relieve more severe pain.Thorough skin care is recommended if you have shingles. Antiseptic or anti-itch lotions, gels and powders are often used to relieve the itching and dry out the blisters. Most of them contain tanins, zinc, menthol or polidocanol. If blisters have already formed, people are sometimes advised to use cooling wraps. But there’s no good scientific research on how well these treatments work.Drugs that fight viruses can be used in people who are over 50 or have a weakened immune system, if the condition is very severe, affects the head and neck area, or there is a higher risk of complications. This is known as "antiviral therapy." Using antiviral medication early on can help speed up recovery and make the pain go away faster. So people are advised to start antiviral therapy no later than 72 hours after the rash starts. In severe cases the medicine can also be given through a drip into a vein (intravenous infusion). If the ear is affected, steroids are often used too. But it still isn’t clear what pros and cons this kind of combination therapy may have.

Drugs for Herpes Zoster (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 447)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
2
Acyclovir Approved Phase 4,Phase 3,Phase 2,Phase 1 59277-89-3 2022
3
Ethanol Approved Phase 4 64-17-5 702
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
7
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
8
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
10
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
11
Capsaicin Approved Phase 4,Phase 3,Phase 2 404-86-4 1548943
12
Natalizumab Approved, Investigational Phase 4 189261-10-7
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
14
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
15
Budesonide Approved Phase 4,Phase 2 51333-22-3 63006 5281004
16
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
17
Tofacitinib Approved, Investigational Phase 4,Phase 2 477600-75-2
18
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
19
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
20
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
21
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
22
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
23
Infliximab Approved Phase 4,Phase 3 170277-31-3
24
Bupivacaine Approved, Investigational Phase 4,Phase 2 2180-92-9, 38396-39-3 2474
25 Vedolizumab Approved Phase 4 943609-66-3
26
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
27
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
28
Certolizumab pegol Approved Phase 4 428863-50-7
29
Mercaptopurine Approved Phase 4 50-44-2 667490
30
Azathioprine Approved Phase 4 446-86-6 2265
31
St. John's Wort Approved, Investigational, Nutraceutical Phase 4 84082-80-4
32
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
35
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
37
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
38
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
39 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
42 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Methylprednisolone Acetate Phase 4,Phase 3,Phase 2,Not Applicable
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 564)
# Name Status NCT ID Phase Drugs
1 The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
2 Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
3 The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
4 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
5 Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine Unknown status NCT02514018 Phase 4
6 Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children Unknown status NCT01982409 Phase 4
7 Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Unknown status NCT00940940 Phase 4
8 Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
9 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Unknown status NCT02383797 Phase 4
10 "Equistasi" and Gait in Hemiparesis Unknown status NCT02714478 Phase 4
11 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
12 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
13 Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care Unknown status NCT01595347 Phase 4 Hyper-oxigenated fatty acid
14 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 Completed NCT01911065 Phase 4
15 Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
16 Safety of a Second Dose of Biken's Varicella Vaccine Completed NCT00830648 Phase 4
17 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
18 ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) Completed NCT01556451 Phase 4
19 Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Completed NCT00885586 Phase 4 gabapentine
20 Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
21 Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT01817270 Phase 4
22 Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) Completed NCT00681031 Phase 4
23 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
24 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
25 Varicella Vaccination With Pulmicort Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
26 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
27 ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) Completed NCT00550745 Phase 4
28 Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis Completed NCT01356004 Phase 4 live attenuated chicken pox vaccine;saline, efficacy
29 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
30 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
31 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
32 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza Completed NCT01693380 Phase 4
33 Palatability Testing of a New Paediatric Formulation of Valacyclovir Completed NCT01682109 Phase 4 Valacyclovir
34 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
35 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
36 An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate Completed NCT02187055 Phase 4 Tofacitinib with methotrexate;Tofacitinib without methotrexate
37 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
38 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
39 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
40 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
41 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation Completed NCT00048165 Phase 4 Daclizumab;Methylprednisolone;Mycophenolate mofetil;Placebo;cyclosporine
42 Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Completed NCT00760747 Phase 4 Atomoxetine
43 The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis Completed NCT01581359 Phase 4 Triptorelin acetate
44 Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients Recruiting NCT03016884 Phase 4
45 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Recruiting NCT03493776 Phase 4
46 Immune Response to Shingles Vaccination Recruiting NCT02624375 Phase 4 Zoster Vaccine Live
47 Zoster Eye Disease Study Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
48 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Recruiting NCT03330171 Phase 4
49 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
50 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia Recruiting NCT03809702 Phase 4 Pregabalin;Placebo

Search NIH Clinical Center for Herpes Zoster

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: herpes zoster

Genetic Tests for Herpes Zoster

Anatomical Context for Herpes Zoster

MalaCards organs/tissues related to Herpes Zoster:

42
Skin, Eye, Testes, Brain, T Cells, Bone, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Zoster:

20
Nerve Fiber

Publications for Herpes Zoster

Articles related to Herpes Zoster:

(show top 50) (show all 3587)
# Title Authors Year
1
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. ( 30885757 )
2019
2
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. ( 30630365 )
2019
3
A case of herpes zoster infection mimicking carpal tunnel syndrome. ( 30860133 )
2019
4
Herpes Zoster Ophthalmicus, Central Retinal Artery Occlusion, and Neovascular Glaucoma in an Immunocompetent Individual. ( 30820294 )
2019
5
Necrotizing Fasciitis Following Herpes Zoster Ophthalmicus in an Immunocompromised Patient. ( 30805235 )
2019
6
Case of herpes zoster with herpetic folliculitis complicated with meningitis: Immunohistochemistry. ( 30888068 )
2019
7
Ultrasound-guided Cervical Nerve Root Block for the Treatment of Acute Cervical Herpes Zoster: A Randomized-controlled Clinical Study. ( 30734476 )
2019
8
Comedones appearing after herpes zoster infection: Koebner phenomenon or Wolf's isotopic response? ( 30734718 )
2019
9
Calabria: a successful experience implementing Herpes Zoster vaccination strategies. ( 30737649 )
2019
10
Herpes Zoster in Pregnancy. ( 30740856 )
2019
11
Mortality risk after herpes zoster infection in end-stage renal disease patients. ( 30746135 )
2019
12
Incidence and risk factors for herpes zoster after adult liver transplantation. ( 30746357 )
2019
13
Association between statin use and herpes zoster: systematic review and meta-analysis. ( 30765397 )
2019
14
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. ( 30776797 )
2019
15
Review: Adjuvant recombinant subunit vaccine prevents herpes zoster more than live attenuated vaccine in adults ≥ 50 years. ( 30776803 )
2019
16
Impact of a multi-component immunization intervention on pneumococcal and herpes zoster vaccinations: A randomized controlled trial of community pharmacies in 2 states. ( 30777645 )
2019
17
Axillary mononeuropathy after herpes zoster infection misdiagnosed as neuropathic pain. ( 30785247 )
2019
18
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. ( 30793003 )
2019
19
Altered gray matter volume in patients with herpes zoster and postherpetic neuralgia. ( 30799946 )
2019
20
Adult vaccination as the cornerstone of successful ageing: the case of herpes zoster vaccination. A European Interdisciplinary Council on Ageing (EICA) expert focus group. ( 30805865 )
2019
21
AF1q gene polymorphism proteomic markers in herpes zoster-infected leukemia patients. ( 30821139 )
2019
22
Vaccine Prevention of Herpes Zoster in Organ Transplant Recipients: A Busy Intersection of Immune Responses to Foreign Antigens. ( 30843045 )
2019
23
Herpes Zoster Ophthalmicus Review and Prevention. ( 30844951 )
2019
24
Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. ( 30848293 )
2019
25
Herpes zoster ophthalmicus pseudodendrites: for topical antivirals or not? ( 30850997 )
2019
26
Herpes zoster onset 9 years after first varicella zoster vaccination in a 11 year old child - a case report. ( 30887925 )
2019
27
Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case. ( 30897230 )
2019
28
Simultaneous parotitis and ipsilateral herpes zoster ophthalmicus: coincidence? ( 30898945 )
2019
29
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. ( 30900514 )
2019
30
An Association Between Herpes Zoster Vaccination and Stroke Reduction Among Elderly Individuals. ( 30901393 )
2019
31
Herpes zoster vaccination efficacy in the long-term care facility population: a qualitative systematic review. ( 30913912 )
2019
32
The eMERGE genotype set of 83,717 subjects imputed to ~40 million variants genome wide and association with the herpes zoster medical record phenotype. ( 30298529 )
2019
33
High-thoracic ultrasound-guided erector spinae plane block for acute herpes zoster pain management in emergency department. ( 30340986 )
2019
34
Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. ( 30367401 )
2019
35
Herpes zoster and the risks of osteoporosis and fracture: a nationwide cohort study. ( 30460416 )
2019
36
Herpes zoster of the external ear. ( 30604491 )
2019
37
Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective. ( 30605536 )
2019
38
Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. ( 30608953 )
2019
39
Evaluation of VZV-specific Cell-mediated Immunity by Interferon-gamma ELISA in Adults ≥50 Years of Age Administered a Herpes Zoster Vaccine. ( 30613990 )
2019
40
Trends in U.S. Community hospitalizations due to herpes zoster: 2001-2015. ( 30616954 )
2019
41
Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children. ( 30628536 )
2019
42
Herpes zoster infection. ( 30630827 )
2019
43
Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study. ( 30636941 )
2019
44
Models for optimally controlling varicella and herpes zoster by varicella vaccination: a comparative study. ( 30652233 )
2019
45
Economic Analysis of Herpes Zoster in a Hospital Setting in Hong Kong. ( 30653238 )
2019
46
Herpes zoster ophthalmicus. ( 30655269 )
2019
47
Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. ( 30660981 )
2019
48
Disseminated herpes zoster following treatment with benralizumab. ( 30666793 )
2019
49
Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis, a case report. ( 30672104 )
2019
50
Update in Herpes Zoster Prevention and the Role of Dermatologists ( 30681788 )
2019

Variations for Herpes Zoster

Expression for Herpes Zoster

Search GEO for disease gene expression data for Herpes Zoster.

Pathways for Herpes Zoster

Pathways related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 HLA-A HLA-B IFNA2 IFNG IL10 IL2
2
Show member pathways
12.62 HLA-A HLA-B IFNA2 IFNG IL10 IL2
3
Show member pathways
12.42 HLA-A HLA-B IFNA2 IFNG IL2
4
Show member pathways
12.37 HLA-A HLA-B IFNA2 IFNG
5
Show member pathways
12.23 IFNA2 IFNG IL10 IL2
6 12.06 FCGR3A IFNA2 IFNG IL10
7 11.97 FCGR3A HLA-A HLA-B
8 11.91 FCGR3A HLA-A HLA-B
9
Show member pathways
11.89 IFNG IL10 IL2
10
Show member pathways
11.81 HLA-A IFNG IL2
11 11.73 IFNA2 IFNG IL10 IL2
12 11.7 IFNA2 IFNG IL10 IL2
13 11.64 IFNG IL10 IL2
14
Show member pathways
11.64 HLA-A HLA-B IFNA2 IFNG IL10 IL2
15
Show member pathways
11.58 FCGR3A HLA-A HLA-B IFNA2 IFNG IL2
16
Show member pathways
11.51 HLA-A IFNG IL2
17 11.43 IFNA2 IFNG IL10 IL2
18 11.39 GYPC IFNG IL10
19 11.33 IFNG IL10 IL2
20 11.31 FCGR3A IFNG IL10 IL2
21 11.22 HLA-B IFNA2 IFNG
22 11.07 IFNG IL2
23 11.07 IFNG IL10 IL2
24 11.02 HLA-A HLA-B
25 10.91 IFNG IL10 IL2

GO Terms for Herpes Zoster

Cellular components related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-A HLA-B
2 MHC class I protein complex GO:0042612 8.62 HLA-A HLA-B

Biological processes related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.81 IFNA2 IFNG IL10 IL2
2 interferon-gamma-mediated signaling pathway GO:0060333 9.58 HLA-A HLA-B IFNG
3 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.54 HLA-A HLA-B
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNA2 IFNG IL2
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.52 HLA-A HLA-B
6 positive regulation of T cell mediated cytotoxicity GO:0001916 9.49 HLA-A HLA-B
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.48 IFNA2 IFNG
8 regulation of regulatory T cell differentiation GO:0045589 9.46 IFNG IL2
9 regulation of immune response GO:0050776 9.46 COL17A1 FCGR3A HLA-A HLA-B
10 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.43 HLA-A HLA-B
11 type I interferon signaling pathway GO:0060337 9.43 HLA-A HLA-B IFNA2
12 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.32 HLA-A HLA-B
13 immune response GO:0006955 9.1 FCGR3A HLA-A HLA-B IFNG IL10 IL2
14 protection from natural killer cell mediated cytotoxicity GO:0042270 8.96 HLA-A HLA-B

Molecular functions related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNA2 IFNG IL10 IL2

Sources for Herpes Zoster

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....